Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -34,058 | -62,421 | -282,024 | -212,162 | -152,618 |
| Depreciation Amortization | 18,854 | 9,428 | 37,955 | 28,502 | 19,018 |
| Accounts receivable | -30,421 | -13,707 | -24,027 | -22,837 | -8,152 |
| Other Working Capital | -53,935 | 21,271 | -105,611 | -73,974 | -64,526 |
| Other Operating Activity | 47,280 | 23,809 | 120,742 | 90,314 | 72,391 |
| Operating Cash Flow | $-52,280 | $-21,620 | $-252,965 | $-190,157 | $-133,887 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | 40,000 | 40,000 | 40,000 |
| PPE Investments | -114 | -114 | -59 | -59 | -59 |
| Sale Of Investment | N/A | N/A | 40,000 | N/A | N/A |
| Other Investing Activity | 0 | 0 | -40,000 | 0 | 0 |
| Investing Cash Flow | $-114 | $-114 | $39,941 | $39,941 | $39,941 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 7,536 | 7,545 | 88,948 | 83,545 | 67,063 |
| Other Financing Activity | 40,000 | 40,000 | 44,783 | 44,783 | 44,783 |
| Financing Cash Flow | $47,536 | $47,545 | $133,731 | $128,328 | $111,846 |
| Beginning Cash Position | 151,839 | 151,839 | 231,132 | 231,132 | 231,132 |
| End Cash Position | 146,981 | 177,650 | 151,839 | 209,244 | 249,032 |
| Net Cash Flow | $-4,858 | $25,811 | $-79,293 | $-21,888 | $17,900 |
| Free Cash Flow | |||||
| Operating Cash Flow | -52,280 | -21,620 | -252,965 | -190,157 | -133,887 |
| Capital Expenditure | -114 | -114 | -59 | -59 | -59 |
| Free Cash Flow | -52,394 | -21,734 | -253,024 | -190,216 | -133,946 |